CorMedix Inc. (CRMD)

Market Cap	292.15M
Revenue (ttm)	n/a
Net Income (ttm)	-46.34M
Shares Out	54.81M
EPS (ttm)	-0.91
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	412,455
Open	5.48
Previous Close	5.45
Day's Range	5.28 - 5.49
52-Week Range	2.57 - 7.00
Beta	1.89
Analysts	Strong Buy
Price Target	13.00 (+143.9%)
Earnings Date	May 13, 2024

About CRMD

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States. Its lead product candidate is DefenCath, an antimicrobial catheter lock solution to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 2010
• Employees: 82
• Stock Exchange: NASDAQ
• Ticker Symbol: CRMD

Analyst Forecast

According to 4 analysts, the average rating for CRMD stock is "Strong Buy." The 12-month stock price forecast is $13.0, which is an increase of 143.90% from the latest price.

Price Target

$13.0

(143.90% upside)

Analyst Consensus: Strong Buy